These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34158340)

  • 1. TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
    Murray BW; Zhai D; Deng W; Zhang X; Ung J; Nguyen V; Zhang H; Barrera M; Parra A; Cowell J; Lee DJ; Aloysius H; Rogers E
    Mol Cancer Ther; 2021 Sep; 20(9):1499-1507. PubMed ID: 34158340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALK
    Zhang X; Tong J; Wang T; Wang Z; Gu S; Xu L; Hou T; Pan P
    Comput Biol Med; 2024 Dec; 183():109265. PubMed ID: 39405725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
    EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
    Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
    Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants.
    Xiao X; Xu Y; Yu X; Chen Y; Zhao W; Xie Z; Zhu X; Xu H; Yang Y; Zhang P
    Bioorg Med Chem Lett; 2023 Jun; 89():129309. PubMed ID: 37127101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
    Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
    Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
    J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with Next-Generation ALK Inhibitors Fuels Plasma
    Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT
    Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
    Wang H; Wang Y; Guo W; Du B; Huang X; Wu R; Yang B; Lin X; Wu Y
    Drug Des Devel Ther; 2018; 12():1183-1193. PubMed ID: 29785088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
    Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
    Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
    Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
    Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.